{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-009897","form_type":"8-K","ticker":"ABSI","cik":"0001672688","company_name":"Absci Corp","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.087571+00:00","generated_at":"2026-06-17T09:18:20.377457+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Absci Q4 2022 net loss $19.5M; full-year loss $104.9M; cash $164.4M; 10 new Active Programs in 2023","bullets":["Q4 2022 revenue $1.6M, net loss $19.5M vs $25.2M loss in Q4 2021.","Full-year 2022 revenue $5.7M, net loss $104.9M vs $101.0M loss in 2021.","Cash, equivalents, and short-term investments $164.4M as of Dec 31, 2022, down from $252.6M.","Achieved zero-shot generative AI creation of de novo antibodies; hit rate 5-30x greater than baselines.","2023 outlook: at least 10 new Active Programs; gross cash use ~$90M, below prior year $105M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-009897","json":"https://secwatch.observer/filing/0001628280-23-009897.json","markdown":"https://secwatch.observer/filing/0001628280-23-009897.md","text":"https://secwatch.observer/filing/0001628280-23-009897.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672688/000162828023009897/0001628280-23-009897-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672688/000162828023009897/absc-20230330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:18:20.377457+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"11041344e0f32aae36195a26aa71847932e80e9e","claim":"Absci Corp reported Fourth Quarter ended December 31, 2022 results: net income Net loss was $19.5 million for the fourth quarter of 2022, as compared to $25.2 million for the corresponding prior year.","evidence_excerpt":"Revenue was $1.6 million for the three months ended December 31, 2022 compared to $1.5 million for the three months ended December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672688/000162828023009897/0001628280-23-009897-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth Quarter ended December 31, 2022"},{"label":"Net income","value":"Net loss was $19.5 million for the fourth quarter of 2022, as compared to $25.2 million for the corresponding prior year"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"11041344e0f32aae36195a26aa71847932e80e9e","claim":"Absci Corp reported Fourth Quarter ended December 31, 2022 results: net income Net loss was $19.5 million for the fourth quarter of 2022, as compared to $25.2 million for the corresponding prior year.","evidence_excerpt":"Net loss was $19.5 million for the fourth quarter of 2022, as compared to $25.2 million for the corresponding prior year period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672688/000162828023009897/0001628280-23-009897-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth Quarter ended December 31, 2022"},{"label":"Net income","value":"Net loss was $19.5 million for the fourth quarter of 2022, as compared to $25.2 million for the corresponding prior year"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"3862cd282129cdd8719a36f212dba1838faf17b6","claim":"Absci Corp reported Full Year ended December 31, 2022 results: net income Net loss was $104.9 million for the year ended December 31, 2022 compared to $101.0 million for the year ended December.","evidence_excerpt":"Revenue was $5.7 million for the year ended December 31, 2022 compared to $4.8 million for the year ended December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672688/000162828023009897/0001628280-23-009897-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year ended December 31, 2022"},{"label":"Net income","value":"Net loss was $104.9 million for the year ended December 31, 2022 compared to $101.0 million for the year ended December"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"3862cd282129cdd8719a36f212dba1838faf17b6","claim":"Absci Corp reported Full Year ended December 31, 2022 results: net income Net loss was $104.9 million for the year ended December 31, 2022 compared to $101.0 million for the year ended December.","evidence_excerpt":"Net loss was $104.9 million for the year ended December 31, 2022 compared to $101.0 million for the year ended December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672688/000162828023009897/0001628280-23-009897-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year ended December 31, 2022"},{"label":"Net income","value":"Net loss was $104.9 million for the year ended December 31, 2022 compared to $101.0 million for the year ended December"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}